Colorectal liver metastases rarely occur in patients with chronic hepatitis virus infection

Hepato-Gastroenterology

Volumn 59, Issue 117, 2012, Pages 1390-1392

  Wang, Feng Shan ^a   Shao, Zi Gong ^a   Zhang, Jia Lin ^a   Liu, Yong Feng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Colorectal liver metastases; Hepatitis virus

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC HEPATITIS; COLORECTAL CANCER; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COLONIC NEOPLASMS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS E; HUMANS; INCIDENCE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84865181048     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11747     Document Type: Article

References (24)

1. Coimbra FJ, Pires TC, Costa Junior WL, Diniz AL, Ribeiro HS: Advances in surgical treatment of colorectal liver metastases. Rev Assoc Med Bras 2011; 57(2);220-227.
2. Faivre J, Manfredi S, Bouvier AM: Epidemiology of colorectal cancer liver metastases. Bull Acad Natl Med 2003; 187:815-822 discussion 22-23.
3. Geoghegan JC, Scheele J: Treatment of colorectal liver metastases. Br J Surg 1999; 86:158-169.
4. Rastogi T, Hildesheim A, Sinha R: Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer 2004; 4:909-917.
5. Welch JP, Donaldson GA: The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189:496-502.
6. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H: Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 1999; 86:332-337.
7. Bajwa A, Blunt N, Vyas S, et al.: Primary tumor resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol 2009; 35(2):164-167.
8. Utsunomiya T, Matsumata T: Metastatic carcinoma in the cirrhotic liver. Am J Surg 1993; 166:776.
9. Realdi G, Bortolotti F, Alberti A, Fattovich G, Ongaro G: Infection due to hepatitis B virus and host immune response. Boll 1st Sieroter Milan 1976; 55(4):323-334.
10. Hess G, Rossol S, Voth R, et al.: Modification of the immune response against hepatitis B virus by the human immunodeficiency virus. Rheumatol Int 1989; 9(3-5):175-179.
11. Gil-Guerrero L, Sarobe P, Prieto J: New therapies for hepatitis C. Med Clin (Barc) 2006; 127(3):104-112.
12. Liaw YF: Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29(1):100-107.
13. Villeneuve JP: The natural history of chronic hepatitis B virus infection. J Clin Virol 2005; 34(1):S139-142.
14. Wong SY, Hynes RO: Tumor-lymphatic interactions in an activated stromal microenvironment. J Cell Biochem 2007; 101(4):840-850.
15. Ceauşu RA, Cîmpean AM, Gaje P, Gurzu S, Jung I, Raica M: CD105/Ki67 double immunostaining expression in liver metastases from colon carcinoma. Rom J Morphol Embryol 2011; 52(2):613-616.
16. Liaw YF, Lee CS, Tsai SL, et al.: T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995; 22:1368-1373.
17. Dienes HP, Drebber U: Pathology of immune-mediated liver injury. Dig Dis 2010; 28(1):57-62.
18. Giannandrea M, Pierce RH, Crispe IN: Indirect action of tumor necrosis factor-alpha in liver injury during the CD8+T cell response to an adeno-associated virus vector in mice. Hepatology 2009; 49(6):2010-2020.
19. Frelin L, Wahlström T, Tucker AE, et al.: A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol 2009; 83(3):1379-1392.
20. Ando K, Hiroishi K, Kaneko T, et al.: Perforin, Fas/Fas ligand and TNF-a pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997; 158:5283-5291.
21. Cao DY, Yang JY, Yue SQ, et al.: Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma. Cell Immunol 2009; 259(1):13-20.
22. Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F: Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int J Cancer 1991; 49(1):19-24.
23. Egilmez NK, Kilinc MO: Tumor-resident CD8+ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression. Arch Immunol Ther Exp (Warsz) 2010; 58(6):399-405.
24. Schuurman B, Heuff G, Beelen RHJ, et al.: Enhanced human Kupffer cell-mediated cytotoxicity after activation of the effector cells and modulation of the target cells by interferon-g: a mechanistic study at the cellular level. Cell Immunol 1995; 165:141-147.